Skip to main content
OpenTrials
Completed

NCT Number: NCT04741334

Mild Head Injury, Antiplatelets, and Anticoagulants

Approximately 20% of patients with mild head injury presenting to the Emergency Department (ED) is taking antiplatelet agents and 10% is taking oral anticoagulants. The aim of the study is to determine the prevalence of cerebral hemorrhage in patients presenting to the ED with an MHI. It also aims to determine whether the use of antiplatelet agents and anticoagulants may be a risk factor for the occurrence of cerebral hemorrhage and mortality. This is a prospective observational study that will include all patients who present to ED at Gemelli Hospital for an MHI for 2 years. Patients will be divided into four groups according to whether or not they are taking anticoagulants and antiplatelet drugs. Groups will be compared to evaluate the possible increased risk of complications in patients on treatment and among the different medications.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Mild head injury (MHI) is one of the most common causes of emergency department (ED) admission. Approximately 20% of MHI patients admitted to PS with a mild traumatic brain injury is taking antiplatelet medications and 10% is taking oral anticoagulants. There are a few data describing the risk of adverse events in patients with MHI taking direct oral anticoagulants (DOAC), and they are of poor quality.

The aim of this study is to investigate the prevalence of cerebral hemorrhage in patients presenting to the ED with an MHI. Moreover, it will be evaluated whether the use of antiplatelet agents and anticoagulants may be a risk factor for the occurrence of cerebral hemorrhage and mortality. This is a prospective observational study that will include all patients who present to the ED at Gemelli Hospital for an MHI for 2 years. Patients will be divided into four groups according to whether or not they are taking anticoagulants and antiplatelet agents. The investigators will then determine the prevalence of cerebral hemorrhage, the need for hospitalization or neurosurgery, and mortality at different follow-up time points for each group. The investigators will compare the groups to assess the potential increased risk in patients on treatment and among drugs.

It can be hypothesized that the use of dicumarol anticoagulants and antiplatelet agents for head injury is associated with a higher risk of cerebral hemorrhage than the use of DOACs. It may be, also, hypothesize that patients taking DOACs are at a higher risk of bleeding than patients not treated with antiplatelet/anticoagulant agents.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients presenting with head trauma within 6 hours from the trauma w
  • Age> 17 years
  • Glasgow Coma Scale (GCS) > 13

Exclusion criteria

  • Presence of serious diseases with a potentially less than one-month prognosis (patient with trauma following syncope from severe cardiovascular disease such as pulmonary embolism, myocardial infarction, ventricular arrhythmias, aortic dissection, aortic aneurysm rupture)
  • Severe trauma in other body areas (identified in the Emergency department by means of CT scan of other body areas such as chest CT, abdomen CT, total body CT).
  • history of congenital or acquired coagulation disorders (Haemophiliacs, patients with severe liver cirrhosis)
  • Patients undergoing dual antiplatelets drugs or combination therapy of antiplatelet and anticoagulant
  • Patients presenting with a GCS>13 and with focal neurologic deficits, suspected sunken fracture, or clinical signs of skull base fracture

Treatment and study plan

direct anticoagulant

Drug

exposure to direct anticoagulant

Other names: DOAC

antiplatelet drugs

Drug

exposure to antiplatelet drugs

Dicumarols

Drug

exposure to dicumarols

Primary outcomes

  1. early Cerebral hemorrhage

    Time frame: 24 hours

    Number of participants with evidence of cerebral hemorrhage at head CT scan

  2. skull fracture

    Time frame: 24 hours

    Number of participants with evidence of skull fracture at head CT scan

  3. Hospital admission

    Time frame: 48 hours

    Number of participants with hospital admission for head trauma complication

Secondary outcomes

  1. early mortality

    Time frame: 24 hours

    Number of participants death from all causes at 1 days

  2. late mortality

    Time frame: 30 days

    Number of participants death from all causes at 30 days

  3. late cerebral hemorrhage

    Time frame: 30 days

    Number of participants with evidence of cerebral hemorrhage at head CT scan

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

Mild Head Injury and Oral Anticoagulants: a Prospective Observational Study

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
Feb 5, 2021
Registry last updated
Mar 31, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.